Nexus (NXU) Q3 2024 earnings summary

Executive summary

• Achieved strong growth in the first nine months of 2024, with sales up 11.4% year-over-year to €190.8m and EBIT up 21.6% to €27.2m.

• Successfully shielded from industry headwinds, driven by digitization projects and new customer wins in Germany, France, and Austria.

• Major acquisitions in Q4 2024 include HD Clinical Ltd (UK/Ireland) and a laboratory information system business in Spain, expected to deliver synergies.

• Continued investment in innovation, AI integration, and product enhancements to support future growth.

Financial highlights

• Revenue rose 11.4% to €190.8m compared to the same period last year; EBITDA increased 15.2% to €40.9m.

• EBIT grew 21.6% to €27.2m; consolidated net income up 16.0% to €20.3m; EPS increased 15.7% to €1.18.

• Operating cash flow was €27.7m, down 4.9% due to higher tax payments; liquidity at €102.5m.

• Share price closed at €55.50 on 30/09/2024, up 7.4% year-over-year; market capitalization €960.2m.

• Employee count averaged 1,853, up 13% year-over-year.

Outlook and guidance

• Management remains confident, citing robust demand from healthcare digitization and regulatory reforms.

• Expects continued growth, leveraging recent acquisitions and ongoing innovation projects.